Ignite Creation Date:
2026-03-26 @ 3:20 PM
Ignite Modification Date:
2026-06-20 @ 10:27 PM
Study NCT ID:
NCT07383818
Status:
RECRUITING
Last Update Posted:
2026-02-03
First Post:
2026-01-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
Sponsor:
First Affiliated Hospital of Zhejiang University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | HR Positive/HER2 Low Breast Cancer | View |